Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia

Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at lea...

Descripción completa

Detalles Bibliográficos
Autores principales: Cross, N C P, White, H E, Colomer, D, Ehrencrona, H, Foroni, L, Gottardi, E, Lange, T, Lion, T, Machova Polakova, K, Dulucq, S, Martinelli, G, Oppliger Leibundgut, E, Pallisgaard, N, Barbany, G, Sacha, T, Talmaci, R, Izzo, B, Saglio, G, Pane, F, Müller, M C, Hochhaus, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430701/
https://www.ncbi.nlm.nih.gov/pubmed/25652737
http://dx.doi.org/10.1038/leu.2015.29

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430701/
https://www.ncbi.nlm.nih.gov/pubmed/25652737
http://dx.doi.org/10.1038/leu.2015.29

Ejemplares similares